Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?

European Heart Journal

Volumn 35, Issue 28, 2014, Pages 1834-1835

  Diener, Hans Christoph ^a   Granger, Christopher B ^b   Patel, Manesh R ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; EDOXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHADS2 SCORE; CLINICAL STUDY; DATA BASE; EDITORIAL; EMBOLISM; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL LIABILITY; MEDICAL SOCIETY; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; RISK REDUCTION; SELECTION BIAS; STROKE UNIT; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; COMPLICATION; FEMALE; MALE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; STROKE; WARFARIN;

EID: 84905005460     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu042     Document Type: Editorial

References (6)

1. Azoulay L, Dell-aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: Early effects on ischaemic strokes. Eur Heart J 2014; 35:1881-1887
2. Mahaffey KW, Hellkamp AS, Patel MR, Hannan KL, Schwabe K, Nessel CC, Berkowitz SD, Halperin JL, Hankey GJ, Becker RC, Piccini JP, Breithardt G, Hacke W, Singer DE, Califf RM, Fox KA. End of study transition from study drug to open-label vitamin K antagonist therapy: The ROCKETAF experience. Circ Cardiovasc Qual Outcomes 2013;6:470-478
3. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013;61:651-658
4. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J 2013;166:549-558
5. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641
6. Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: An individual patient data meta-Analysis of randomised controlled trials. Lancet Neurol 2013;12:539-545.